Loading...
Publication
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.18 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as
vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side
effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most
widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug
for which several nanosized delivery systems have been developed over the years. While it is true that some of
these systems are already in the market, it is also true that research on this subject remains very active and that
there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so
much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative
nanotechnology approaches have emerged.
Description
Keywords
Cancer Chemotherapy Doxorubicin Nanotherapeutics Delivery systems Clinical trials . Faculdade de Ciências Exatas e da Engenharia Centro de Química da Madeira
Citation
Gonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020). A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. Journal of Controlled Release, 317, 347-374. https://doi.org/10.1016/j.jconrel.2019.11.016
Publisher
Elsevier